Mitomycin: ten years after approval for marketing

Area of Science:

• Oncology
• Pharmacology

Background:

• Mitomycin received FDA approval in 1974 for gastric and pancreatic carcinomas.
• It has been widely used in combination chemotherapy for various tumors over the past seven years.

Purpose of the Study:

• To evaluate the defined contribution of mitomycin in combination chemotherapy regimens.
• To assess the drug's activity as a single agent and its safety profile.

Main Methods:

• Review of clinical data and literature on mitomycin's efficacy and toxicity.
• Analysis of its use in systemic versus intravesical treatments.

Main Results:

• Mitomycin shows clear activity as a single agent in intravesical treatment for superficial bladder carcinoma.
• Common toxicities include anorexia, vomiting, and myelosuppression.
• Increasing reports of severe toxicities like fibrosing alveolitis and microangiopathic hemolytic anemia with renal failure exist.

Conclusions:

• The precise role of mitomycin in systemic cancer chemotherapy remains inadequately defined.
• Potential for severe adverse effects necessitates careful consideration for its use beyond investigational purposes.